C ANNA Q & A BUSIN E SS LE A D E R
6 QUESTIONS WITH
DR. STUART TITUS One-on-on time with the CEO of Medical Marijuana Inc. MJNA
BY CHRIS LARKIN Abond trader on Wall Street for 11 years, Dr. Stuart W. Titus went from investing in Medical Marijuana Inc. (MJNA), the first publicly held company vested in medical marijuana and industrial hemp, to becoming its CEO. In between, he earned a Ph.D in physiotherapy and practiced that discipline for 15 years, obtaining a fellowship with the American Academy of Pain Management and a clinical association with the American Association of Integrative Medicine. Titus’ strong background in both finance and healthcare uniquely qualifies him to run MJNA, which provides more than 85 proprietary cannabinoid (CBD) delivery systems that are more socially, medically and legally (at least to the federal government) acceptable than current industry norms.
1: What are three medical problems that CBD shows the most promise in treating? TITUS: Research has shown CBD to be effective and safe for epilepsy in children. This comes from GW Pharma in the U.S., plus our research and studies in Mexico. There are 16 (soon to be 17 with Indiana) CBD-only U.S. States that allow families to possess a cannabis-based product (enough THC to get arrested) for children diagnosed with epilepsy. The second is Alzheimer’s. Early-stage research by Dr. David Schubert from The Salk Institute in San Diego shows 22
CANNA BUSINESS NOW
• CANNBUSINESSNOW.COM
that cannabinoids can reduce brain inflammation as well as the accumulation of beta-amyloid, a toxic protein build-up that is the hallmark of Alzheimer’s. Further research from Stanford University shows that the onset of Alzheimer’s dementia stems from an endogenous cannabinoid deficiency. Finally, digestive disorders, such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) are being studied by our biotech investment group and pharma development company, AXIM Biotech (OTC: AXIM).
